FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2020/09/027595 [Registered on: 04/09/2020] Trial Registered Prospectively
Last Modified On: 02/09/2020
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cross Sectional Study 
Study Design  Single Arm Study 
Public Title of Study   A Study to create an artificial intelligence based risk assessment model to detect deterioration of patients clinical status 
Scientific Title of Study   Artificial Intelligence Based Risk Assessment of Patients Clinical Respiratory Progression Status 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Debendra Kumar Tripathy 
Designation  Additional Professor 
Affiliation  All India Institute of Medical Sciences Rishikesh 
Address  Dept of Anesthesiology and Critical Care AIIMS Rishikesh

Dehradun
UTTARANCHAL
249203
India 
Phone  9443278806  
Fax    
Email  drdebendra@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Debendra Kumar Tripathy 
Designation  Additional Professor 
Affiliation  All India Institute of Medical Sciences Rishikesh 
Address  Dept of Anesthesiology and Critical Care AIIMS Rishikesh


UTTARANCHAL
249203
India 
Phone  9443278806  
Fax    
Email  drdebendra@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Debendra Kumar Tripathy 
Designation  Additional Professor 
Affiliation  All India Institute of Medical Sciences Rishikesh 
Address  Dept of Anesthesiology and Critical Care AIIMS Rishikesh


UTTARANCHAL
249203
India 
Phone  9443278806  
Fax    
Email  drdebendra@gmail.com  
 
Source of Monetary or Material Support  
GE Healthcare Global Research Organization John F Welch Technology Center Wipro GE Healthcare Private Limited, No. 4 Kadugodi Industrial Area, Bangalore 560067, Karnataka, India 
 
Primary Sponsor  
Name  Wipro GE Healthcare Private Limited 
Address  No. 4 Kadugodi Industrial Area, Bangalore 560067, India 
Type of Sponsor  Other [Healthcare Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Debendra Kumar Tripathy  All India Institute of Medical Sciences Rishikesh  Dept. of Anesthesiology and Critical Care Level 6 Medical College Building AIIMS Rishikesh Virbhadra Road Rishikesh
Dehradun
UTTARANCHAL 
9443278806

drdebendra@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
AIIMS Rishikesh  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: B972||Coronavirus as the cause of diseases classified elsewhere,  
 
Intervention / Comparator Agent  
Type  Name  Details 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  All patients admitted with suspected COVID-19 at AIIMS Rishikesh (irrespective of COVID Status) during the study period who are able and willing to give informed written consent (Signature/Thumb impression) 
 
ExclusionCriteria 
Details  Unable or unwilling to give informed consent 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Proof of concept Artificial Intelligence based Risk assessment model   8 weeks 
 
Secondary Outcome  
Outcome  TimePoints 
Testing of iterated model in the clinical setting on prospectively collected datasets   16 weeks 
 
Target Sample Size   Total Sample Size="500"
Sample Size from India="500" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   14/09/2020 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Study Design: Cross-sectional Analytical – Both Retrospective and Prospective

 

Study Setting: Departments of Emergency Medicine, Trauma, Medicine, medicine, Pulmonology, Anaesthesiology and Critical Care, AIIMS Rishikesh

 

Study Population: All patients (minimum 500 patients) admitted to the above departments at AIIMS Rishikesh (irrespective of COVID Status) during the study period satisfying the following criteria.

 

Inclusion Criteria:

1.     Aged 18 years and above.

2.     Able and willing to give informed written consent (Signature/Thumb impression)

Exclusion Criteria:

1.     Unable or unwilling to give informed consent

Requirement for informed consent will be waived off for retrospective patient data with IEC approval.

 

Methods:

 

Phase 1: In Phase 1 of the study, retrospective data of 10-100 patients will be analysed for Model evaluation on GEHC site, iteration and development of initial proof of concept.

 

Phase 2: In Phase 2, prospective data of 100 patients will be used for Testing of initial proof of concept in the clinical setting on prospectively collected datasets.

 

Phase 3: In Phase 3, Testing of the iterated model in the clinical setting on prospectively collected datasets will be done in 500 patients for Performance evaluation of model as a decision support tool in the clinical setting

 

Phase 4: Clinical deployment across multiple hospitals (through separate MOUs)

 

Data Collection

1.     Patient demographics, history, monitor parameters, ventilator parameters, imaging results and lab tests for COVID related illness that are readily available in a consistent format at AIIMS Rishikesh inpatient files/records/systems/e-Hospital will be collected

2.     The associated metadata (ie DICOM tag extraction, if possible EPR data) will be collected and aggregated

3.     Data will be anonymized to remove any patient protected health information (PHI)

a.     Site to keep a PHI-rich copy of the data on-hand

b.     A PHI free copy of the data

4.     Transfer the data via secure media to GE for algorithm development and validation

 

Retrospective/Prospective Data Collection - De-identified datasets for minimum of 100 patients

a.     Demographic datasets including but not limited to Age, Gender, Ethnicity, Weight, Height, ICD-9 code diagnosis, ICD-9 code procedures, ICU Admit Time, ICU Discharge Time, Past Medical History, Hospital Admit Time, Hospital Discharge Time, Mortality (Yes or no, if yes then the time of death)

b.     Lab tests including but not limited to ABG tests, Urea, Creatinine, Electrolytes, Monitor parameters including RR, HR, SpO2, ECG, Blood Pressure Parameters (Invasive & Non-Invasive BP parameters), Temperature

c.     Ventilator parameters including FiO2, FeO2, PEEP, EtCO2, MV, TV, PIP, PP, Intubation Time, Extubation Time, Mode of Ventilation, Ventilator Settings Parameters

d.     Radiology imaging (CT, longitudinal X-ray)

 

Prospective testing and performance evaluation

1.     Deploy a version of the developed algorithm at AIIMS Rishikesh to run on prospectively recruited patient datasets

2.     Record performance of the algorithm against the expected outcome and determine if further development is required

3.     Determine the relevance of the algorithm 

 

Clinical deployment across multiple hospitals (through MOUs)

1.     Determine quickest and most efficient deployment platform accessible for all AIIMS Rishikesh partners

 

Outcomes:

1.     Data Collection and initial proof of concept model build

a.     De-identified datasets to transferred to GEHC data scientists

b.     Proof of concept model results shared with broader collaboration

2.     Prospective evaluation

a.     The model developed is evaluated within 2 weeks of readiness in a controlled environment in AIIMS Rishikesh as a pilot

3.     Deploy algorithm on mass

a.     The deployment model identified and implemented at collaboration sites

b.     Review the option to deploy models nationally

 
Close